Biocon secures marketing partner in Pfizer

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) partnered with Pfizer Inc. (NYSE:PFE) to market Biocon's biosimilar versions of insulin and insulin analog products, including recombinant human insulin, glargine, aspart and lispro. The companies will share co-exclusive rights in Germany, India and Malaysia, while Pfizer will have exclusive rights elsewhere, except in a number of developing markets, where Pfizer will share co-exclusive rights with existing Biocon partners. Biocon will remain responsible for clinical development, regulatory activities and manufacturing and supply of the biosimilars. Pfizer said the deal is in line with its strategy to strengthen its presence in follow-on biologics, as well as diabetes. ...